John Byrd

John C. Byrd , MD

Department Chair

Gordon and Helen Hughes Taylor Endowed Chair & Professor

Medical Sciences Building

COM Internal Medicine - 0551

Education

Bachelor of Arts: Hendrix College Conway, Arkansas, 1987 (Chemistry)

Doctor of Medicine: University of Arkansas Little Rock, Arkansas, 1991

Residency: Walter Reed Army Medical Center Washington, DC, 1994 (Internal Medicine)

Fellowship: Walter Reed Army Medical Center Washington, DC, 1996 (Hematology, Oncology, Bone Marrow Transplantation)

Certifications

American Board of Internal Medicine (Hematology) (Certification Date: 11-14-2007 )

Clinical Interests

Hematology and Oncology

Leukemia

Acute Lymphocytic Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Chronic Myelogenous Leukemia

Myelodysplastic Syndrome

Specialities

Hematology

Internal Medicine

Medical Oncology

Research Support

Grant: #UG1CA233338 07-01-2021 -02-28-2022 National Cancer Institute ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies Role:PI 1469675.45 Hold Level:Federal

Grant: #UG1CA233338 07-01-2021 -02-28-2022 National Cancer Institute ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies Role:PI 1469675.45 Hold Level:Federal

Grant: #R35CA197734 Investigators:Byrd, John; Scaglioni, Pier Paolo 07-01-2021 -08-31-2022 National Cancer Institute Targeted Therapy for Leukemia Role:PI 170582.23 Hold Level:Federal

Grant: #K99CA246083 (Actual PI: Fellow Abdul-Aziz, Amina) Investigators:Abdul-Aziz, Amina; Byrd, John; Scaglioni, Pier Paolo 09-01-2021 -01-31-2022 National Cancer Institute Impact of the senescent bone marrow microenvironment in AML biology Role:PI 76161.00 Awarded Level:Federal

Grant: #Alliance for Clinical Trials in Oncology Investigators:Byrd, John 02-01-2022 -01-31-2029 Brigham and Women's Hospital, Inc. Alliance for Clinical Trials in Oncology Role:PI 0.00 Hold Level:Non Profit

Grant: #R01CA213442 07-01-2021 -02-28-2022 National Cancer Institute Unlocking the Potential of PI3K Inhibition in CLL Role:PI 84130.60 Hold Level:Federal

Grant: #R01CA213442 07-01-2021 -02-28-2022 National Cancer Institute Unlocking the Potential of PI3K Inhibition in CLL Role:PI 84130.60 Hold Level:Federal

Grant: #NX-2127-001 Investigators:Byrd, John 12-01-2021 -12-01-2024 Precision for Medicine A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies Role:PI 308602.66 Hold Level:Industry

Grant: #IOV-CLL-01 09-01-2021 -09-01-2024 Iovance Biotherapeutics, Inc. A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Role:PI 0.00 Hold Level:Industry

Grant: #IOV-CLL-01 09-01-2021 -09-01-2024 Iovance Biotherapeutics, Inc. A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Role:PI 0.00 Hold Level:Industry

Grant: #TL-895-209 04-01-2022 -03-31-2025 Telios Pharma, Inc An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naive Myelofibrosis (MF) Subjects Role:PI 241305.26 Hold Level:Industry

Grant: #TL-895-209 04-01-2022 -03-31-2025 Telios Pharma, Inc An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naive Myelofibrosis (MF) Subjects Role:PI 241305.26 Hold Level:Industry

Publications

Peer Reviewed Publications

Larkin, Karilyn T M; Byrd, John C (2021. ) Whole-genome sequencing for myeloid disease: one assay to stratify them all?.Nature reviews. Clinical oncology, , More Information

Korman, Abraham M; Hastings, Justin G; Byrd, John C; Kaffenberger, Benjamin H (2017. ) Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia.JAMA dermatology, , 153 (1 ) ,108-110 More Information

Flinn, Ian W; Ruppert, Amy S; Harwin, William; Waterhouse, David; Papish, Steven; Jones, Jeffrey A; Hainsworth, John; Byrd, John C (2016. ) A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.American journal of hematology, , 91 (10 ) ,1020-5 More Information

Sanchez-Aguilera, A; Rattmann, I; Drew, D Z; Müller, L U W; Summey, V; Lucas, D M; Byrd, J C; Croce, C M; Gu, Y; Cancelas, J A; Johnston, P; Moritz, T; Williams, D A (2010. ) Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia.Leukemia, , 24 (1 ) ,97-104 More Information

Treon, Steven P.; Agus, David B.; Link, Brian; Rodrigues, Gilberto; Molina, Arturo; Lacy, Martha Q.; Fisher, David C.; Emmanouilides, Christos; Richards, Arthur I.; Clark, Bruce; Lucas, Marjorie S.; Schlossman, Robert; Schenkein, David; Lin, Boris; Kimby, Eva; Anderson, K. C.; Byrd, John C. (2001. ) CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. Journal of immunotherapy : official journal of the Society for Biological Therapy, , 24 (3 ) ,272-279